罗格列酮联合二甲双胍治疗非酒精性脂肪肝病研究

Efficacy of rosiglitazone combined with metformin on patients with non - alcoholic fatty live diseases

目的探讨罗格列酮联合二甲双胍对非酒精性脂肪性肝病（NAFLD）患者的治疗作用。方法将120例NAFLD患者随机分为对照组、罗格列酮治疗组、罗格列酮联合二甲双胍治疗组（联合组）。疗程均为6个月，比较各自治疗前后的体质量指数、血脂、肝酶学、空腹血糖、空腹胰岛素及胰岛素抵抗指数（HOMA—IR），记录症状、体征、肝脏B超表现。结果药物治疗组患者的总胆固醇、甘油三酯、血清丙氨酸氨基转移酶，天门冬氨酸氨基转移酶、HOMA—IR均较治疗前明显改善（P〈0．05）；联合治疗组体质量下降明显（P〈0．05），总有效率明显高于对照组（P〈0．01）。结论罗格列酮对NAFLD的治疗有效，联合二甲双胍效果优于单独应用。

Objective To study the efficacy of rosiglitazone combined with mefformin on patients with non - alcoholic fatty liver diseases （NAFLD）. Methods One hundred and twenty patients with non - alcoholic fatty liver disease were randomly divided into three groups： control group, rosiglitazone treatment group, and rosiglitazone combined with metformin treatment group, 6 months were one cycle in all three groups. The evaluating indexes including body mass index（BMI） , blood lipid, liver enzyme activities, fasting blood glucose （ FPG）, fasting blood insulin （ FBI）, insulin resistance index （ IRI）, clinical symptoms, physical signs, and results of B - ultrasonic examination in liver. Results The patients trea- ted with rosiglitazone or combined with metformin, levels of TC, TG, ALT, AST and IRI were obviously improved than those before treatment（ P 〈 0.05）. The patients treated with rosightazone combined with metformin, levels of BMI were obviously improved than those before treatment（ P 〈 0.05）. The total effective rates in these groups were significantly higher than that in control group （ P 〈 0.01 ）. Conclusions The treatment of pioglitazone is safe and effective to NAFLD, and the therapeutic effect of combination use is superior to that of pioglitazone or metformin use alone.